TY - JOUR
T1 - Colchicine kinetics in patients with familial Mediterranean fever
AU - Halkin, Hillel
AU - Dany, Sanda
AU - Greenwald, Mark
AU - Shnaps, Yitschak
AU - Tirosh, Moshe
PY - 1980/7
Y1 - 1980/7
N2 - Serum colchicine levels were determined by radioimmunoassay after a 1‐mg bolus injected intravenously in 4 patients with familial Mediterranean fever and in 6 normal subjects. Mean elimination half‐life (t½) (±SEM) was 157 ± 20 min in the patients and 65 ± 15 min in the normal subjects (p < 0.005). Total clearance was 239 ± 50 ml/min in the patients and 601 ± 155 ml/min in the normal subjects (p < 0.05). Volume of distribution (Vdarea) was 76 ± 16 and 49 ± 9 l and did not differ significantly. In 8 patients receiving colchicine prophylactically with good clinical response, serum colchicine ranged from 0.3 to 2.4 ng/ml after daily doses of 1 mg orally. In 2 responding patients 2‐mg doses orally induced levels from 4 to 10 ng/ml, and in one (a nonresponder) a 3‐mg dose induced levels of 7.5 to 13 ng/ml. Of 3 patients receiving 2 mg daily with unsatisfactory clinical responses, serum levels were not detectable in one and in the low range of 1.5 to 5.4 ng/ml in the others. It is suggested that lack of response to colchicine orally in some nonresponders could result from inadequate absorption or altered disposition of colchicine. Clinical Pharmacology and Therapeutics (1980) 28, 82–87; doi:
AB - Serum colchicine levels were determined by radioimmunoassay after a 1‐mg bolus injected intravenously in 4 patients with familial Mediterranean fever and in 6 normal subjects. Mean elimination half‐life (t½) (±SEM) was 157 ± 20 min in the patients and 65 ± 15 min in the normal subjects (p < 0.005). Total clearance was 239 ± 50 ml/min in the patients and 601 ± 155 ml/min in the normal subjects (p < 0.05). Volume of distribution (Vdarea) was 76 ± 16 and 49 ± 9 l and did not differ significantly. In 8 patients receiving colchicine prophylactically with good clinical response, serum colchicine ranged from 0.3 to 2.4 ng/ml after daily doses of 1 mg orally. In 2 responding patients 2‐mg doses orally induced levels from 4 to 10 ng/ml, and in one (a nonresponder) a 3‐mg dose induced levels of 7.5 to 13 ng/ml. Of 3 patients receiving 2 mg daily with unsatisfactory clinical responses, serum levels were not detectable in one and in the low range of 1.5 to 5.4 ng/ml in the others. It is suggested that lack of response to colchicine orally in some nonresponders could result from inadequate absorption or altered disposition of colchicine. Clinical Pharmacology and Therapeutics (1980) 28, 82–87; doi:
UR - http://www.scopus.com/inward/record.url?scp=0018854265&partnerID=8YFLogxK
U2 - 10.1038/clpt.1980.135
DO - 10.1038/clpt.1980.135
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 7389258
AN - SCOPUS:0018854265
SN - 0009-9236
VL - 28
SP - 82
EP - 87
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
IS - 1
ER -